4//SEC Filing
Brennan Kevin M. 4
Accession 0001193125-25-297207
CIK 0001840233other
Filed
Nov 24, 7:00 PM ET
Accepted
Nov 25, 4:10 PM ET
Size
19.2 KB
Accession
0001193125-25-297207
Insider Transaction Report
Form 4
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
Transactions
- Award
Stock Option (right to buy)
2025-11-21+131,700→ 131,700 totalExercise: $0.84Exp: 2035-10-07→ Common Stock (131,700 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-11-21−55,000→ 0 totalExercise: $3.17Exp: 2033-03-31→ Common Stock (55,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-11-21−25,000→ 0 totalExercise: $2.79Exp: 2033-08-15→ Common Stock (25,000 underlying) - Award
Stock Option (right to buy)
2025-11-21+20,000→ 20,000 totalExercise: $1.00Exp: 2034-04-30→ Common Stock (20,000 underlying) - Award
Stock Option (right to buy)
2025-11-21+55,000→ 55,000 totalExercise: $1.00Exp: 2033-03-31→ Common Stock (55,000 underlying) - Award
Stock Option (right to buy)
2025-11-21+25,000→ 25,000 totalExercise: $1.00Exp: 2033-08-15→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2025-11-21−20,000→ 0 totalExercise: $1.08Exp: 2034-04-30→ Common Stock (20,000 underlying)
Footnotes (6)
- [F1]On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 1 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025.
- [F2]This option vests in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
- [F3]This option was granted on April 1, 2023 and vested on March 30, 2024 with respect to 25% of the shares of common stock underlying the stock option. The remaining 75% of the shares of common stock underlying the stock option continues to vest in 36 equal monthly installments thereafter through March 30, 2027.
- [F4]The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect.
- [F5]Immediately exercisable.
- [F6]This option was granted on May 1, 2024. The shares underlying the option began vesting on June 1, 2024 and continue to vest in equal monthly installments thereafter through May 1, 2028.
Documents
Issuer
Xilio Therapeutics, Inc.
CIK 0001840233
Entity typeother
Related Parties
1- filerCIK 0001971303
Filing Metadata
- Form type
- 4
- Filed
- Nov 24, 7:00 PM ET
- Accepted
- Nov 25, 4:10 PM ET
- Size
- 19.2 KB